PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsMecasermin rinfabate
Mecasermin rinfabate
Increlex, Iplex (mecasermin rinfabate) is a protein pharmaceutical. Mecasermin rinfabate was first approved as Iplex on 2005-12-12. It has been approved in Europe to treat laron syndrome.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
musculoskeletal diseasesD009140
hereditary congenital and neonatal diseases and abnormalitiesD009358
endocrine system diseasesD004700
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Mecasermin rinfabate
Tradename
Proper name
Company
Number
Date
Products
Iplexmecasermin rinfabateInsmedN-21884 DISCN2005-12-12
1 products
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration
Code
mecasermin rinfabate, Iplex, Insmed Incorporated
2112-12-12Orphan excl.
Patent Expiration
No data
ATC Codes
H: Systemic hormonal preparations, excl. sex hormones and insulins
— H01: Pituitary and hypothalamic hormones and analogues
— H01A: Anterior pituitary lobe hormones and analogues
— H01AC: Somatropin and somatropin agonists
— H01AC05: Mecasermin rinfabate
HCPCS
No data
Clinical
Clinical Trials
254 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AcromegalyD000172———4961130
Laron syndromeD046150Orphanet_633E34.3213634519
Pituitary dwarfismD004393EFO_1001109E23.034—4616
DwarfismD004392—E34.311532311
Failure to thriveD005183——124128
Cognitive dysfunctionD060825—G31.84—1—146
Heart failureD006333EFO_0003144I5012—136
Chronic kidney failureD007676EFO_0003884N18.6———224
LeukemiaD007938—C95———112
Brain injuriesD001930—S06.9———112
Show 19 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
ObesityD009765EFO_0001073E66.9121—811
AnorexiaD000855—R63.0233—27
Anorexia nervosaD000856EFO_0004215F50.0233—27
Endocrine system diseasesD004700EFO_0001379E34.9121—37
Growth disordersD006130———23—26
SyndromeD013577——112—25
FibromyalgiaD005356EFO_0005687M79.1—21—25
Pituitary diseasesD010900—E23.7—12—14
Breast neoplasmsD001943EFO_0003869C50—21—24
FibrosisD005355——122—14
Show 33 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369—C8054——614
Insulin resistanceD007333EFO_0002614E88.81922——36
OsteoporosisD010024EFO_0003882M81.011——34
SarcomaD012509———2——24
Myofascial pain syndromesD009209EFO_1001054——2——24
Rare diseasesD035583———1——34
Colorectal neoplasmsD015179——11——13
Rectal neoplasmsD012004———3———3
Healthy volunteers/patients————1——23
Retinopathy of prematurityD012178EFO_1001158H35.1—3———3
Show 80 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Cystic fibrosisD003550EFO_0000390E842———13
AgingD000375GO_0007568R41.811———12
GliomaD005910EFO_0000520—1————1
Brain stem neoplasmsD020295EFO_1001767—1————1
PinealomaD010871——1————1
Squamous cell carcinoma of head and neckD000077195——1————1
Joint instabilityD007593——1————1
TendinopathyD052256EFO_1001434M77.91————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Alzheimer diseaseD000544EFO_0000249F03————22
Bone fracturesD050723EFO_0003931T14.8————22
Wounds and injuriesD014947—T14.8————22
Motor activityD009043EFO_0003940—————22
Metabolic bone diseasesD001851——————22
OverweightD050177—E66.3————22
Igg deficiencyD017099—D80.3————22
SchizophreniaD012559EFO_0000692F20————22
StrokeD020521EFO_0000712I63.9————22
Macular degenerationD008268EFO_0001365H35.30————11
Show 92 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameMecasermin rinfabate
INNmecasermin rinfabate
Description
Mecasermin rinfabate (INN, USAN) (brand name Iplex), also known as rhIGF-1/rhIGFBP-3, is a drug consisting of recombinant human insulin-like growth factor 1 (IGF-1) and recombinant human insulin-like growth factor binding protein-3 (IGFBP-3) which is used for the treatment of amyotrophic lateral sclerosis (Lou Gehrig's disease).
Classification
Protein
Drug classgrowth factors: insulin-like growth factors
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID—
RxCUI—
ChEMBL IDCHEMBL1201717
ChEBI ID—
PubChem CID—
DrugBank—
UNII IDNZ8M50KKRG (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Increlex – Eton Pharmaceuticals
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 5,051 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
804 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use